Document is current

Article History

Received: 8 November 2023

Accepted: 28 January 2024

First Online: 4 March 2024

Declarations

:

: MH received personal fees from AstraZeneca, Chugai, Lilly, Pfizer, Cmic and Daiichi-Sankyo. NH received consulting fees from Roche Diagnostics K.K., and received honoraria for lectures from Daiichi-Sankyo and Pfizer. SN received honoraria for lectures from Eli Lilly, Pfizer, Chugai, Taiho, Eisai, MSD, Daiichi-Sankyo, and AstraZeneca. KN received research funding from Chugai, Kyowa-Kirin, Eisai and Daiichi-Sankyo, and received honoraria for lectures from Pfizer, Lilly, Daiichi-Sankyo, Eisai, Kyowa-Kirin and Chugai. YO received honoraria for lectures from Daiichi Sankyo, Pfizer, and Kyowa-Kirin. YM received consulting fees from Lilly and Roche, and received honoraria for lectures from Agilent technologies, Chugai, Ono, MSD and Daiichi-Sankyo. TS received honoraria for lectures from Chugai, Daiichi-Sankyo, MSD, Agilent/DAKO and Roch Diagnostics, and participated on an advisory board of Roche Diagnostics. YT received research funding from Daiichi-Sankyo, Lilly, MSD, and Taiho. JT received research grants from Eisai and Ohtsuka, received consulting fees from Daiichi-Sankyo and AstraZeneca, and received honoraria for lectures from Daiichi-Sankyo and Taiho. T Takano received honoraria for lectures from Chugai, Daiichi-Sankyo, and Lilly, SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo, received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon Kayaku, participated on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD, is an executive member of JBCRG, JBCS, JSMO, and BIG. SM received a research funding from Chugai, and received honoraria for lecture from Chugai and Daiichi-Dankyo. RH received a research funding from Roche Diagnostics, received honoraria for lecture from Chugai, MSD, US-Lead, Roche Diagnostics, Daiichi-Sankyo, Pfizer, AstraZeneca, payment for manuscript writing from Medical View, Bunkodo, Shinoharashinsha Publishing, Ishiyaku Publishers, Nakayama Shoten, Nanzando and Elsevier Japan, and participation on advisory board of Daiichi-Sankyo, Roche Diagnostic and Chugai. HT received grants from Goryo chemical and Roche Diagnostic, received scholarship donations from Chugai, Takeda and Lilly, received honoraria for lecture from Roche Diagnostics, Daiichi-Sankyo, MSD, Chugai, Eisi, Kyowa-Kirin and AstraZeneca, received payments for expert testimony from Roche Diagnostics and Konica Minoruta and is a member of the board of directors of JBCS. RY is a member of the board of directors of JBCS. T Toyama received research funding from Chugai, Lilly, Takeda, Kyowa-Kirin, Daiichi-Sankyo Nippon Kayaku and Eisai, and received honoraria for lectures from Pfizer, Daiichi-Sankyo, Novartis, AstraZeneca, Takeda and Chugai. CY received an honorarium for lecture from Daiichi-Sankyo. MT received research grants from Chugai, Takeda, Pfizer, Taiho, JBCRG assoc., KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science and Sanwa Shurui, received honoraria for lecture or lecture chair from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, and Sysmex, participated on advisory boards of Daiichi-Sankyo, Eli Lilly and companies, BMS, Athenex Oncology, Bertis, Terumo, and Kansai Medical Net, is a member of the directors of JBCRG, KBCRN, NPO org. OOTR and is a chair of the board of director of JBCS, and is associate editors of British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, Asian Journal of Breast Surgery. YY received research funding from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Taiho, Takeda, Lilly, Pfizer and Novartis, received honoraria for lecture from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Lilly, Pfizer, Daiichi-Sankyo, Nippon Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex and Exact Science, participated on advisory boards of AstraZeneca, Chugai, Novartis, MSD, Lilly, Pfizer and Daiichi-Sankyo, and is a member of the board of directors of JBCS and JBCRG. The other authors declare no relevant conflicts of interest.